Sotera Health Files 8-K for Regulation FD Disclosure

TL;DR

Sotera Health filed an 8-K, likely for a public disclosure event.

AI Summary

Sotera Health Co. filed an 8-K on May 16, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or transactional details, but serves as a notification of information being made public.

Why It Matters

This filing indicates Sotera Health is making information public under Regulation FD, which ensures fair disclosure of material information to all investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not appear to contain negative or significant new information.

Key Players & Entities

• Sotera Health Co (company) — Registrant
• Regulation FD (regulation) — Disclosure type
• May 16, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.01 — ge on which registered Common stock, $0.01 par value per share SHC The Nasdaq Stoc

Filing Documents

• shc-20240516.htm (8-K) — 27KB
• 0001822479-24-000022.txt ( ) — 151KB
• shc-20240516.xsd (EX-101.SCH) — 2KB
• shc-20240516_lab.xml (EX-101.LAB) — 22KB
• shc-20240516_pre.xml (EX-101.PRE) — 13KB
• shc-20240516_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Sotera Health Holdings, LLC ("SHH"), a direct subsidiary of Sotera Health Company (the "Company"), plans to initiate discussions with lenders to refinance its existing term loans through a combination of a new term loan and other secured debt (the "Refinancing"). The existing term loans are outstanding under both the First Lien Credit Agreement dated as of December 13, 2019 by and among the Company, SHH, certain subsidiaries of the Company, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders and issuing banks party thereto and the First Lien Credit Agreement dated as of February 23, 2023, by and among the Company, SHH, JPMorgan Chase Bank, N.A., as First Lien Administrative Agent and the lenders party thereto. The Refinancing and the terms thereof are subject to market and other conditions, and there can be no assurance as to whether or when such Refinancing may be completed, or as to the actual size or terms thereof. This report is neither an offer to sell nor a solicitation of an offer to purchase any securities. The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly incorporated by specific reference in such filing.

Forward-looking Statements

Forward-looking Statements This report contains forward-looking statements that reflect management's expectations about future events and speak only as of the date hereof. You can identify these forward-looking statements by the use of forward-looking words such as "intends" or other comparable words. Any forward-looking statements contained in this report are based upon current plans, estimates and expectations in light of information currently available to us. The inclusion of this forward-looking information should not be regarded as a representation by us that the future plans, estimates or expectations contemplated by us will be achieved. These forward-looking statements are subject to various risks, uncertainties and assumptions including, without limitation, the risk that the Company will not be able to complete the Refinancing in a timely manner or at all, the risk that any new indebtedness in connection with the Refinancing will not be available on favorable terms or at all and the risk that the Company will be unable to pay down the balance of the existing credit facilitates as intended. For additional discussion of these risks and uncertainties, please refer to the Company's other filings with the SEC, such as its annual and quarterly reports. We do not undertake any obligation to publicly update or revise these forward-looking statements, except as required by law.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sotera Health Company (Registrant) Date: May 16, 2024 By: /s/ Jonathan M. Lyons Jonathan M. Lyons Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR